Understanding BMS-986094 Cardiotoxicity using Human iPSC-Derived Cardiomyocytes
- 11 February 2021
- Resource Type: Posters, Toxicology & Safety
BMS-986094 (INX-08189) is a guanosine nucleotide analogue prodrug which was developed to treat hepatitis C virus (HCV). However, BMS-986094 was discontinued in Phase III clinical trials with 1 death and 8 people hospitalised with significantly reduced left ventricular ejection fraction (LVEF). Cardiotoxic effects were observed in 14 out of the 34 patients with left ventricular dysfunction, with ST depressions, T-wave inversions or loss of T-wave amplitude.
In this poster, we focus on:
- investigating the mechanism behind the cardiotoxicity of BMS-986094
- the use of MEA and human iPSC-derived cardiomyocytes in long term incubations with BMS-986094
Read our poster to learn more about our research!
Sounds interesting?
Enter your details below to continue reading…
